Rheumnow Podcast
ACR24 - Day4c
Nov 22, 2024
Join Dr. David Liew, a renowned rheumatologist, as he dives into the role of JAK inhibitors in treating polymyalgia rheumatica. He discusses the recent breakthroughs that are reshaping treatment strategies and making these therapies more accessible. The conversation also turns to the cardiovascular risks associated with JAK inhibitors, compared to traditional steroid use. Liew's insights highlight the importance of evaluating both benefits and risks in personalized rheumatology care.
14:34
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The study revealed that strict routine lab monitoring may not be necessary for all rheumatological patients, indicating a shift towards personalized medicine.
- Promising results from JAK inhibitors, particularly for PMR, suggest potential benefits in reducing steroid exposure and improving patient outcomes.
Deep dives
Lab Monitoring in Rheumatology Treatments
A study analyzing the adherence to routine blood monitoring among patients treated for rheumatological conditions revealed that only 19% followed the recommended three-month testing interval. Most lab abnormalities detected were not clinically significant, indicating that strict monitoring may be unnecessary for all patient groups. The findings suggest a push towards personalized medicine, taking into consideration individual risk factors, medication types, and comorbidities for each patient. This approach could not only optimize patient care but also reduce the healthcare cost burden associated with frequent lab tests.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
